Analyst Price Target is $54.00
▲ +59.29% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Sanuwave Health in the last 3 months. The average price target is $54.00, with a high forecast of $55.00 and a low forecast of $53.00. The average price target represents a 59.29% upside from the last price of $33.90.
Current Consensus is
Moderate Buy
The current consensus among 4 contributing investment analysts is to moderate buy stock in Sanuwave Health. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.
Read More
